Common vitamin D receptor variants showed no clear link to colorectal cancer
The tested genetic variants were not significantly associated with colorectal cancer in a meta-analysis, offering little support for their use as risk markers.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The tested vitamin D receptor variants were not significantly associated with colorectal cancer susceptibility across the genetic models examined. This weakens the case for using these variants alone as risk markers. It does not establish that all vitamin D pathways are irrelevant, and it does not test whether vitamin D supplements prevent cancer.
The abstract does not provide individual odds ratios or confidence intervals, making the range of effects compatible with the data difficult to assess. Nonsignificant results do not demonstrate exact equivalence between genetic groups.
What researchers found
Colorectal cancer susceptibility
Across tested allele and genotype comparisons in case-control studies; assessment periods were not reported. Individual odds ratios were not supplied in the abstract.
What was tested
Researchers examined common variants of the vitamin D receptor gene under different genetic models. These comparisons concern inherited markers and cancer status; the study did not assign participants a vitamin supplement.
How to read the null result
The authors reported high statistical power and argued that inadequate sample size was unlikely to explain the null findings. Missing effect estimates still make the range of plausible associations difficult to assess.
The original publication
A Lack of Association between Vitamin D Receptor Gene Polymorphisms with Colorectal Cancer: A Comprehensive Meta-Analysis and Power Assessment.
Anilkumar AS, Thomas SM, Veerabathiran R
Crit Rev Eukaryot Gene Expr · 2026
- PubMed ID
- 41824933
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.